TY - JOUR
T1 - Compression of Morbidity Is Observed Across Cohorts with Exceptional Longevity
AU - Ismail, Khadija
AU - Nussbaum, Lisa
AU - Sebastiani, Paola
AU - Andersen, Stacy
AU - Perls, Thomas
AU - Barzilai, Nir
AU - Milman, Sofiya
N1 - Funding Information:
This work was supported by funding from the National Institute on Aging (NIA) (Nussbaum L, Sebastiani P, Andersen S, Perls T: The Longevity Consortium, U19AG023122). Grants from the National Institutes of Health (NIH) (P01AG021654) (NB), the Glenn Center for the Biology of Human Aging (Paul Glenn Foundation for Medical Research) (NB), NIH/NIA 1 R01 AG 042188–01 (NB). This publication was supported in part by Clinical and Translational Science Awards UL1 TR001073, TL1 TR001072, KL2 TR001071 from the National Center for Advancing Translational Sciences, a component of the NIH (SM) and by a Medical Student Training in Aging Research grant administered by the American Federation for Aging Research and the NIA (KI). Nir Barzilai is the scientific founder and a stockholder, patent holder, and board member of CohBar Inc. This company has no relationship to this study. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Author Contributions: Ismail, Nussbaum, Sebastiani, Perls, Andersen, Barzilai, Milman: study conception, design, acquisition and interpretation of data, drafting and revising manuscript. All authors approved the final version of the manuscript for submission. Sponsor's Role: None.
Publisher Copyright:
© 2016, Copyright the Authors Journal compilation © 2016, The American Geriatrics Society
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Objectives: To determine, in a sample of Ashkenazi Jewish aged 95 and older, whether there is a compression of morbidity similar to what has been reported in other cohorts with exceptional longevity. Design: Case–control study. Setting: Longevity Genes Project (LGP) and New England Centenarian Study (NECS). Participants: LGP (n = 439, mean age 97.8 ± 2.8) and NECS (n = 1,498, mean age 101.4 ± 4.0) participants with exceptional longevity and their respective younger referent cohorts (LGP, n = 696; NECS, n = 302). Measurements: Self- and proxy reports of age of onset of cancer, cardiovascular disease, diabetes mellitus, hypertension, osteoporosis, and stroke. Results: Long-lived individuals from LGP and NECS had later age of onset of cancer, cardiovascular disease, diabetes mellitus, hypertension, and osteoporosis than their respective younger reference groups. The risk of overall morbidity was lower in participants with exceptional longevity than in younger participants (NECS men: relative risk (RR) = 0.12, women: RR = 0.20; LGP men: RR = 0.18, women: RR = 0.24). The age at which 20% of each of the groups with exceptional longevity experienced specific diseases was between 18 and 24 years later than in the reference groups, stratified according to sex. Conclusion: The similar extension of health span and compression of morbidity seen in NECS and LGP participants with exceptional longevity further validates the utility of these rare individuals for the study of factors that delay or prevent a broad spectrum of diseases otherwise associated with mortality and disability.
AB - Objectives: To determine, in a sample of Ashkenazi Jewish aged 95 and older, whether there is a compression of morbidity similar to what has been reported in other cohorts with exceptional longevity. Design: Case–control study. Setting: Longevity Genes Project (LGP) and New England Centenarian Study (NECS). Participants: LGP (n = 439, mean age 97.8 ± 2.8) and NECS (n = 1,498, mean age 101.4 ± 4.0) participants with exceptional longevity and their respective younger referent cohorts (LGP, n = 696; NECS, n = 302). Measurements: Self- and proxy reports of age of onset of cancer, cardiovascular disease, diabetes mellitus, hypertension, osteoporosis, and stroke. Results: Long-lived individuals from LGP and NECS had later age of onset of cancer, cardiovascular disease, diabetes mellitus, hypertension, and osteoporosis than their respective younger reference groups. The risk of overall morbidity was lower in participants with exceptional longevity than in younger participants (NECS men: relative risk (RR) = 0.12, women: RR = 0.20; LGP men: RR = 0.18, women: RR = 0.24). The age at which 20% of each of the groups with exceptional longevity experienced specific diseases was between 18 and 24 years later than in the reference groups, stratified according to sex. Conclusion: The similar extension of health span and compression of morbidity seen in NECS and LGP participants with exceptional longevity further validates the utility of these rare individuals for the study of factors that delay or prevent a broad spectrum of diseases otherwise associated with mortality and disability.
KW - compression of morbidity
KW - health span
KW - longevity
KW - older adults
UR - http://www.scopus.com/inward/record.url?scp=84982311253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982311253&partnerID=8YFLogxK
U2 - 10.1111/jgs.14222
DO - 10.1111/jgs.14222
M3 - Article
C2 - 27377170
AN - SCOPUS:84982311253
SN - 0002-8614
VL - 64
SP - 1583
EP - 1591
JO - Journal of the American Geriatrics Society
JF - Journal of the American Geriatrics Society
IS - 8
ER -
